Market Closed -
Nasdaq
21:00:00 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
3.83
USD
|
-0.52%
|
|
+3.79%
|
+25.57%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,452
|
742.9
|
400.6
|
254.5
|
324.3
|
-
|
-
|
Enterprise Value (EV)
1 |
2,602
|
-21.44
|
-246.1
|
-321.2
|
-218.6
|
-124.2
|
-23.96
|
P/E ratio
|
-81.9
x
|
6.53
x
|
-3.46
x
|
-1.87
x
|
-1.4
x
|
-1.32
x
|
-2.96
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
71
x
|
2.11
x
|
-
|
-
|
-
|
7.93
x
|
2.7
x
|
EV / Revenue
|
53.5
x
|
-0.06
x
|
-
|
-
|
-
|
-3.04
x
|
-0.2
x
|
EV / EBITDA
|
-236
x
|
-0.15
x
|
1.89
x
|
1.96
x
|
1.04
x
|
0.64
x
|
0.13
x
|
EV / FCF
|
8.77
x
|
0.25
x
|
2
x
|
3.76
x
|
1.76
x
|
0.54
x
|
0.11
x
|
FCF Yield
|
11.4%
|
406%
|
50%
|
26.6%
|
56.7%
|
186%
|
897%
|
Price to Book
|
1.65
x
|
1.05
x
|
0.63
x
|
0.46
x
|
0.86
x
|
1.44
x
|
2.03
x
|
Nbr of stocks (in thousands)
|
82,617
|
83,103
|
83,288
|
83,436
|
84,223
|
-
|
-
|
Reference price
2 |
41.78
|
8.940
|
4.810
|
3.050
|
3.850
|
3.850
|
3.850
|
Announcement Date
|
30/03/21
|
28/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
48.63
|
351.4
|
-
|
-
|
-
|
40.87
|
120.2
|
EBITDA
1 |
-
|
-11.01
|
138.4
|
-130.4
|
-163.7
|
-210.4
|
-194.6
|
-190.7
|
EBIT
1 |
-
|
-11.03
|
138.4
|
-130.6
|
-164.2
|
-212.9
|
-218.9
|
-190.7
|
Operating Margin
|
-
|
-22.68%
|
39.38%
|
-
|
-
|
-
|
-535.53%
|
-158.72%
|
Earnings before Tax (EBT)
1 |
-
|
-10.95
|
138.6
|
-119.5
|
-134.9
|
-231.5
|
-263.5
|
-250
|
Net income
1 |
-14.03
|
-10.95
|
121.2
|
-115.9
|
-136
|
-230.8
|
-245.8
|
-149.9
|
Net margin
|
-
|
-22.51%
|
34.49%
|
-
|
-
|
-
|
-601.52%
|
-124.75%
|
EPS
2 |
-1.390
|
-0.5100
|
1.370
|
-1.390
|
-1.630
|
-2.759
|
-2.924
|
-1.301
|
Free Cash Flow
1 |
-
|
296.7
|
-87.01
|
-122.9
|
-85.4
|
-124
|
-231
|
-215
|
FCF margin
|
-
|
610.1%
|
-24.76%
|
-
|
-
|
-
|
-565.25%
|
-178.9%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/06/20
|
30/03/21
|
28/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
32.81
|
192.2
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-22.14
|
121.2
|
-42.17
|
-32.25
|
-16.18
|
-39.8
|
-41.46
|
-35.13
|
-40.68
|
-46.47
|
-59
|
-70
|
-75
|
-79
|
EBIT
1 |
-22.15
|
121.2
|
-42.18
|
-32.3
|
-16.28
|
-39.9
|
-41.57
|
-35.24
|
-40.78
|
-46.57
|
-54.56
|
-62.19
|
-65.06
|
-68.56
|
Operating Margin
|
-67.5%
|
63.06%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-22.09
|
121.2
|
-42.08
|
-31.22
|
-11.9
|
-34.31
|
-35.27
|
-27.93
|
-32.92
|
-38.82
|
-49.48
|
-57.54
|
-60.5
|
-63.94
|
Net income
1 |
-28.19
|
117.1
|
-42.08
|
-31.34
|
-8.066
|
-34.43
|
-35.47
|
-28.18
|
-33.14
|
-39.16
|
-50.66
|
-57.26
|
-59.67
|
-63.29
|
Net margin
|
-85.93%
|
60.95%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3400
|
1.320
|
-0.5100
|
-0.3800
|
-0.1000
|
-0.4100
|
-0.4300
|
-0.3400
|
-0.4000
|
-0.4700
|
-0.6058
|
-0.6823
|
-0.7086
|
-0.7556
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
28/02/22
|
10/05/22
|
08/08/22
|
07/11/22
|
28/02/23
|
08/05/23
|
08/08/23
|
08/11/23
|
28/02/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
850
|
764
|
647
|
576
|
543
|
448
|
348
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
297
|
-87
|
-123
|
-85.4
|
-124
|
-231
|
-215
|
ROE (net income / shareholders' equity)
|
-
|
-4.39%
|
19.3%
|
-17.2%
|
-22.7%
|
-41.2%
|
-70.7%
|
-149%
|
ROA (Net income/ Total Assets)
|
-
|
-2.47%
|
14.8%
|
-16.1%
|
-21.6%
|
-46.3%
|
-66.1%
|
-83%
|
Assets
1 |
-
|
442.9
|
818.3
|
719.8
|
630.8
|
498.2
|
372
|
180.7
|
Book Value Per Share
2 |
-
|
25.40
|
8.540
|
7.700
|
6.660
|
4.500
|
2.670
|
1.900
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/06/20
|
30/03/21
|
28/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
3.85
USD Average target price
4.667
USD Spread / Average Target +21.21% Consensus |
1st Jan change
|
Capi.
|
---|
| +25.57% | 324M | | -1.65% | 104B | | +6.75% | 97.47B | | +5.71% | 22.25B | | -12.60% | 21.68B | | -9.70% | 18.2B | | -39.98% | 17.02B | | -10.17% | 16.36B | | +6.12% | 14.39B | | +35.47% | 12.37B |
Bio Therapeutic Drugs
|